API Holdings, India's largest digital healthcare platform and the ultimate parent company of Thyrocare, has become debt-free after repaying its outstanding debt of Rs 1,050 crore, funded through proceeds from the recent sale of a portion of its stake in Thyrocare Technologies and internal accruals.
The development comes after Docon Technologies Private Limited, the promoter and holding company of Thyrocare, sold 1,57,69,696 Thyrocare shares, representing around 9.90 per cent of the company’s paid-up equity share capital, through market trades. Following the sale, Docon continues to remain the promoter and holding company of Thyrocare with a 51.02 per cent stake.
The debt payment has also resulted in the release of the pledge on the remaining Thyrocare shares held by Docon. The entire outstanding pledge linked to the debt has now been released, leaving Docon’s 51.02 per cent holding in Thyrocare fully unencumbered.
Alok Kumar Jagnani, Whole-Time Director and Group CFO, API Holdings, said, “We’ve repaid our term debt in full, and we did it the hard way, without diluting our stake in Thyrocare below 51 per cent. That’s the real headline: a stronger balance sheet without giving up our ownership. It reflects a capital allocation philosophy where growth and discipline aren’t traded off against each other. With every business in the group soon profitable, there’s no drag left on the P&L ; just a clean base to build from.”
Siddharth Shah, Vice Chairman, API Holdings, said, “The Thyrocare acquisition has worked out well for API. Shareholders who held on instead of tendering to our open offer at Rs 433 a share in July 2021 (bonus adjusted) are sitting on Rs 653 at close of trading on 14th August 2026 - dividends included. That’s a 51 per cent return. NIFTY 50 gave you 41 per cent. Pathology peers weren’t even close. True value for money! Congratulations to the Thyrocare team, a turnaround nobody thought was possible.”
Rahul Guha, MD & CEO, API Holdings and Thyrocare, said, “Zero debt isn’t the finish line; it's the starting gun. This wasn’t financial engineering; it was Thyrocare’s and the group's execution, quarter after quarter, that made it possible. What the team proved is bigger than a balance sheet: this organisation can execute on anything it sets its mind to. That’s the real asset we’re carrying into the next chapter.”
